Peanut AllergyPhase 1/2NCT07117669
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
A Phase 1/2 study testing ENP-501 in people with Peanut Allergy, run by N-Fold, LLC at 1 site in United States.
Trial summary
This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA) Read more about this study
- Who is it for?
- Ages 14 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Peanut Allergy
- What is being tested?
- ENP-501
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 68 participants
- Where
- 1 siteUnited States
- Study dates
- 16 Dec 2025to Nov 2028
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 50 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Part 1:
- 14-50 years of age (inclusive)
- Otherwise medically healthy and able to participate in the study
- Able to perform spirometry testing in accordance with the American Thoracic Society (ATS) guidelines (2019)
- All women of child-bearing potential, agree to either abstain from sexual activity or agree to use an adequate method of contraception for the duration of the study and for 30 days after the last dose of investigational product
- Signed and dated written informed consent from the participant and/or parent or guardian
Show all 31Show fewer
- Signed and dated assent from participant under 18 in accordance with local IRB regulations
- Willing and able to avoid peanut and peanut contaminants for the duration of the trial
- Part 1 Cohort 1 only (NPA Participants)
- No known clinical history of peanut allergy with regular exposure to peanuts in daily life, i.e ingests peanuts without symptoms
- Negative Skin Prick Test (SPT) (wheal diameter of <3 mm) to peanut
- Part 1 Cohort 2 only (PA Participants)
- A documented clinical history of peanut allergy, which includes the development of symptoms (e.g., urticaria, flushing, rhinorrhea and sneezing, throat tightness or hoarseness, wheezing, vomiting) verified by a physician
- At least two of the three following requirements:
- Positive Skin Prick Test (SPT) (wheal diameter of ≥ 8 mm) to peanut
- An elevated serum peanut specific IgE level ≥ 7 kUA/L (ImmunoCAP®)
- An Ara-h2 IgE level of ≥ 2 kUA/L (ImmunoCAP®)
- Part 2:
- 14 to 50 years of age (inclusive)
- A documented clinical history of peanut allergy, which includes the development of symptoms (e.g., urticaria, flushing, rhinorrhea and sneezing, throat tightness or hoarseness, wheezing, vomiting) verified by a physician
- At least two of the three following requirements at screening:
- Positive SPT (wheal diameter of ≥ 3 mm) to peanut
- Serum peanut-specific IgE level ≥ 0.7 kUA/L (ImmunoCAP®)
- An Ara-h2 IgE level of ≥ 0.5 kUA/L (ImmunoCAP®) within 1 year of enrollment
- Participant must be willing and able to complete a DBPCFC at screening and EOT (24-hours after last dose) and experience dose-limiting symptoms at or before the 300 mg challenge dose of peanut protein during a Double Blind, Placebo Controlled Food Challenge (DBPCFC) conducted in accordance with Practical Issues in Allergology, Joint United States/European Union Initiative (PRACTALL) guidelines
- Otherwise medically healthy and able to participate in the study
- Able to perform spirometry testing in accordance with the ATS guidelines (2019)
- All women of child-bearing potential, agree to either abstain from sexual activity or agree to use an adequate method of contraception for the duration of the study and for 30 days after the last dose of investigational product
- Signed and dated written informed consent from the participant and/or parent or guardian
- Signed and dated assent from participant under 18 in accordance with local IRB regulations
- Willing and able to avoid peanut and peanut contaminants for the duration of the trial
Who cannot join
- History of severe anaphylactic event requiring mechanical ventilation or use of intravenous (IV) vasopressor drugs
- Clinically significant screening electrocardiogram (ECG) abnormality or corrected QTcF >/= 450 msec at Screening
- FEV1 value < 80% predicted at Screening
- Any hospitalization in the past year for asthma, >1 course of oral steroids for asthma in the past 6 months, or any emergency room visit in the past 6 months for asthma
- Poorly controlled atopic dermatitis
- Eosinophilic gastrointestinal disease
Show all 19Show fewer
- Use of oral or IV corticosteroids within 30 days of Screening
- Use of tricyclic antidepressants within 6 months of Screening
- Inability to discontinue antihistamines for at least 5 half-lives before skin testing
- Use of omalizumab or other immunomodulatory therapy (not including corticosteroids) or biologic therapy within one year of Screening
- Use of any food allergen-specific or other non-traditional form of allergen immunotherapy within one year of Screening
- Use of immunosuppressive drugs within 30 days of Screening
- Use of ß-blockers (oral)
- Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies including urinalysis
- Pregnant or breast-feeding (if female)
- Behavioral, cognitive, or psychiatric disease that in the opinion of the Investigator affects the ability of the participant to understand and cooperate with the study protocol
- Known allergy to inactive ingredients of investigational product (active or placebo)
- Participation in another interventional clinical trial within 30 days of Screening or within 5 half-lives of the other IP
- Residing at the same address as another participant in this or any peanut immunotherapy study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Research Site 001
Aurora, Colorado, 80045
About this study
Official title: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ENP-501 in Non-Peanut Allergic Participants and Participants With a Known Peanut Allergy
This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)
- Conditions
- Peanut Allergy
- Being tested
- ENP-501, Placebo
- Keywords
- Peanut Hypersensitivity
- Medical subject headings
- Peanut Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ENP-501Drug
- Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks
- Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose
PlaceboDrug
- Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks
- Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose
| Study group | Role | What they receive |
|---|---|---|
| ENP-501 | Experimental | Not described Receives: Drug: ENP-501 |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v 5.0 in Part 1
Measured: Up to 22 Weeks
Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) as Assessed by NCI CTCAE v 5.0 in Part 1
Measured: Up to 22 Weeks
Number of Participants with Dose Limiting Toxicities (DLTs) as Assessed by NCI CTCAE v 5.0 in Part 1
Measured: Up to 22 Weeks
Number of Participants with Systemic Reactions as Assessed by NCI CTCAE v 5.0 in Part 1
Measured: Up to 22 Weeks
Number of Participants with changes in Clinical Laboratory Values in Part 1
Measured: Up to 22 Weeks
Number of Participants with changes in Physical Examination in Part 1
Measured: Up to 22 Weeks
Number of Participants with changes in Vital Signs in Part 1
Measured: Up to 22 Weeks
Proportion of Participants Tolerating ≥1043 mg Cumulative Peanut Protein Without Dose-Limiting Symptoms at End of Treatment (EOT) Visit Double-Blind Placebo-Controlled Food Challenge (DBPCFC) Compared to Placebo in Part 2
Measured: Up to 72 Weeks
Secondary outcomes (29)
Number of Participants Able to Tolerate 2000 µg Dose of ENP-501 Without Experiencing Dose-Limiting Toxicity (DLT) in Part 1
Measured: Up to 22 Weeks
Change in Total IgE Levels in Part 1
Measured: Screening and Week 22 (EOS)
Change in Ara h 1-Specific IgE Levels in Part 1
Measured: Screening and Week 22 (EOS)
Change in Ara h 2-Specific IgE Levels in Part 1
Measured: Screening and Week 22 (EOS)
Change in Ara h 3-Specific IgE Levels in Part 1
Measured: Screening and Week 22 (EOS)
Change in Ara h 1-Specific IgG4 Levels in Part 1
Measured: Screening and Week 22 (EOS)
Change in Ara h 2-Specific IgG4 Levels in Part 1
Measured: Screening and Week 22 (EOS)
Change in Ara h 3-Specific IgG4 Levels in Part 1
Measured: Screening and Week 22 (EOS)
Change in Wheal Diameter on Skin Prick Test (SPT) to Peanut in Part 1
Measured: Screening and Week 22 (EOS)
Proportion of Participants Tolerating at Least 443 mg Cumulative Dose of Peanut Protein Without Dose-Limiting Symptoms at EOT Visit DBPCFC Compared to Placebo in Part 2
Measured: Up to 72 Weeks
Proportion of Participants Tolerating at Least 2043 mg Cumulative Dose of Peanut Protein Without Dose-Limiting Symptoms at EOT Visit DBPCFC Compared to Placebo in Part 2
Measured: Up to 72 Weeks
Proportion of Participants Tolerating 4043 mg Cumulative Dose of Peanut Protein Without Dose-Limiting Symptoms at EOT Visit DBPCFC Compared to Placebo in Part 2
Measured: Up to 72 Weeks
Maximum Severity of Symptoms Occurring at Each Challenge Dose of Peanut Protein During the Exit DBPCFC in Part 2
Measured: Up to 72 Weeks
Number of Participants Able to Tolerate the 2000 µg Dose of ENP-501 in Part 2
Measured: Up to 72 Weeks
Change in Total IgE Levels in Part 2
Measured: Screening and Week 72 (EOS)
Change in Ara h 1-Specific IgE Levels in Part 2
Measured: Screening and Week 72 (EOS)
Change in Ara h 2-Specific IgE Levels in Part 2
Measured: Screening and Week 72 (EOS)
Change in Ara h 3-Specific IgE Levels in Part 2
Measured: Screening and Week 72 (EOS)
Change in Ara h 1-Specific IgG4 Levels in Part 2
Measured: Screening and Week 72 (EOS)
Change in Ara h 2-Specific IgG4 Levels in Part 2
Measured: Screening and Week 72 (EOS)
Change in Ara h 3-Specific IgG4 Levels in Part 2
Measured: Screening and Week 72 (EOS)
Change in Wheal Diameter on Skin Prick Test (SPT) to Peanut in Part 2
Measured: Screening and Week 72 (EOS)
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v 5.0 in Part 2
Measured: Up to 72 Weeks
Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) as Assessed by NCI CTCAE v 5.0 in Part 2
Measured: Up to 72 Weeks
Number of Participants with TEAEs leading to discontinuation as Assessed by NCI CTCAE v 5.0 in Part 2
Measured: Up to 72 Weeks
Number of Participants with Systemic Reactions as Assessed by NCI CTCAE v 5.0 in Part 2
Measured: Up to 72 Weeks
Number of Participants with changes in Clinical Laboratory Values in Part 2
Measured: Up to 72 Weeks
Number of Participants with changes in Physical Examination in Part 2
Measured: Up to 72 Weeks
Number of Participants with changes in Vital Signs in Part 2
Measured: Up to 72 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2025
- Study start16 Dec 2025
- Primary completionNov 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peanut AllergyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 68 participants (estimated)
Sponsor and investigators
- Lead sponsor
- N-Fold, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- CBCC Global Research
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07117669
- Sponsor's protocol ID
- ENP-501-001
- Status last verified
- Apr 2026
- First submitted
- 4 Aug 2025
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ENP-501 in Non-Peanut Allergic Participants and Participants With a Known Peanut Allergy
- ClinicalTrials.gov ID
- NCT07117669
- Acronym / sponsor ID
- ENP-501-001
- Conditions
- Peanut Allergy
- Keywords
- Peanut Hypersensitivity
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 68 participants (estimated)
- Lead sponsor
- N-Fold, LLCIndustry (pharma, biotech, devices)
- Collaborators
- CBCC Global Research
- Study start
- 16 Dec 2025 (actual)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 12 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ENP-501 | Experimental | Drug: ENP-501 |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 14 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (31 listed)
- 14-50 years of age (inclusive)
- Otherwise medically healthy and able to participate in the study
- Able to perform spirometry testing in accordance with the American Thoracic Society (ATS) guidelines (2019)
- All women of child-bearing potential, agree to either abstain from sexual activity or agree to use an adequate method of contraception for the duration of the study and for 30 days after the last dose of investigational product
- Signed and dated written informed consent from the participant and/or parent or guardian
Key exclusion criteria (19 listed)
- History of severe anaphylactic event requiring mechanical ventilation or use of intravenous (IV) vasopressor drugs
- Clinically significant screening electrocardiogram (ECG) abnormality or corrected QTcF >/= 450 msec at Screening
- FEV1 value < 80% predicted at Screening
- Any hospitalization in the past year for asthma, >1 course of oral steroids for asthma in the past 6 months, or any emergency room visit in the past 6 months for asthma
- Poorly controlled atopic dermatitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ENP-501* Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks * Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose | Drug | ENP-501 |
| Placebo* Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks * Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose | Drug | Placebo |
Primary outcome
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v 5.0 in Part 1
Time frame: Up to 22 Weeks
Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) as Assessed by NCI CTCAE v 5.0 in Part 1
Time frame: Up to 22 Weeks
Number of Participants with Dose Limiting Toxicities (DLTs) as Assessed by NCI CTCAE v 5.0 in Part 1
Time frame: Up to 22 Weeks
Number of Participants with Systemic Reactions as Assessed by NCI CTCAE v 5.0 in Part 1
Time frame: Up to 22 Weeks
Number of Participants with changes in Clinical Laboratory Values in Part 1
Time frame: Up to 22 Weeks
Number of Participants with changes in Physical Examination in Part 1
Time frame: Up to 22 Weeks
Number of Participants with changes in Vital Signs in Part 1
Time frame: Up to 22 Weeks
Proportion of Participants Tolerating ≥1043 mg Cumulative Peanut Protein Without Dose-Limiting Symptoms at End of Treatment (EOT) Visit Double-Blind Placebo-Controlled Food Challenge (DBPCFC) Compared to Placebo in Part 2
Time frame: Up to 72 Weeks
29 secondary outcomes
Number of Participants Able to Tolerate 2000 µg Dose of ENP-501 Without Experiencing Dose-Limiting Toxicity (DLT) in Part 1
Time frame: Up to 22 Weeks
Change in Total IgE Levels in Part 1
Time frame: Screening and Week 22 (EOS)
Change in Ara h 1-Specific IgE Levels in Part 1
Time frame: Screening and Week 22 (EOS)
Change in Ara h 2-Specific IgE Levels in Part 1
Time frame: Screening and Week 22 (EOS)
Change in Ara h 3-Specific IgE Levels in Part 1
Time frame: Screening and Week 22 (EOS)
Change in Ara h 1-Specific IgG4 Levels in Part 1
Time frame: Screening and Week 22 (EOS)
Change in Ara h 2-Specific IgG4 Levels in Part 1
Time frame: Screening and Week 22 (EOS)
Change in Ara h 3-Specific IgG4 Levels in Part 1
Time frame: Screening and Week 22 (EOS)
Change in Wheal Diameter on Skin Prick Test (SPT) to Peanut in Part 1
Time frame: Screening and Week 22 (EOS)
Proportion of Participants Tolerating at Least 443 mg Cumulative Dose of Peanut Protein Without Dose-Limiting Symptoms at EOT Visit DBPCFC Compared to Placebo in Part 2
Time frame: Up to 72 Weeks
Proportion of Participants Tolerating at Least 2043 mg Cumulative Dose of Peanut Protein Without Dose-Limiting Symptoms at EOT Visit DBPCFC Compared to Placebo in Part 2
Time frame: Up to 72 Weeks
Proportion of Participants Tolerating 4043 mg Cumulative Dose of Peanut Protein Without Dose-Limiting Symptoms at EOT Visit DBPCFC Compared to Placebo in Part 2
Time frame: Up to 72 Weeks
Maximum Severity of Symptoms Occurring at Each Challenge Dose of Peanut Protein During the Exit DBPCFC in Part 2
Time frame: Up to 72 Weeks
Number of Participants Able to Tolerate the 2000 µg Dose of ENP-501 in Part 2
Time frame: Up to 72 Weeks
Change in Total IgE Levels in Part 2
Time frame: Screening and Week 72 (EOS)
Change in Ara h 1-Specific IgE Levels in Part 2
Time frame: Screening and Week 72 (EOS)
Change in Ara h 2-Specific IgE Levels in Part 2
Time frame: Screening and Week 72 (EOS)
Change in Ara h 3-Specific IgE Levels in Part 2
Time frame: Screening and Week 72 (EOS)
Change in Ara h 1-Specific IgG4 Levels in Part 2
Time frame: Screening and Week 72 (EOS)
Change in Ara h 2-Specific IgG4 Levels in Part 2
Time frame: Screening and Week 72 (EOS)
Change in Ara h 3-Specific IgG4 Levels in Part 2
Time frame: Screening and Week 72 (EOS)
Change in Wheal Diameter on Skin Prick Test (SPT) to Peanut in Part 2
Time frame: Screening and Week 72 (EOS)
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v 5.0 in Part 2
Time frame: Up to 72 Weeks
Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) as Assessed by NCI CTCAE v 5.0 in Part 2
Time frame: Up to 72 Weeks
Number of Participants with TEAEs leading to discontinuation as Assessed by NCI CTCAE v 5.0 in Part 2
Time frame: Up to 72 Weeks
Number of Participants with Systemic Reactions as Assessed by NCI CTCAE v 5.0 in Part 2
Time frame: Up to 72 Weeks
Number of Participants with changes in Clinical Laboratory Values in Part 2
Time frame: Up to 72 Weeks
Number of Participants with changes in Physical Examination in Part 2
Time frame: Up to 72 Weeks
Number of Participants with changes in Vital Signs in Part 2
Time frame: Up to 72 Weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
Related trials for Peanut Allergy
Active, not recruitingPhase 2
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Immune System Diseases, Ig-E Mediated Food Allergy
Active, not recruitingPhase 2
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Peanut Allergy, Peanut Hypersensitivity
Not yet recruiting
Oral Immunotherapy for Children With Peanut Allergy
Peanut Allergic Subjects, Peanut Allergies
RecruitingObservational study
Study of Oral Food Challenge Biomarkers (SAFER)
Allergy
Active, not recruitingObservational study
EPAP, Interviewstudy
Food Allergy, Food Allergy Peanut
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing ENP-501 in people with Peanut Allergy, run by N-Fold, LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 31 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Balraj Sangha (+1 (661) 322-2206, balraj.sangha@cbcc.global), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v 5.0 in Part 1 (time frame: Up to 22 Weeks). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.